Summary
Published in Scientific Reports (2023), this peer-reviewed study used 3D Petri Dish® micro-molds to form scaffold-free 3D microtissues. Full citation: Taborska, Pavla, et al. Novel PD-L1- and collagen-expressing patient-derived cell line of undifferentiated pleomorphic sarcoma (JBT19) as a model for cancer immunotherapy
Novel PD-L1- and collagen-expressing patient-derived cell line of undifferentiated pleomorphic sarcoma (JBT19) as a model for cancer immunotherapy
Research Overview
Undifferentiated pleomorphic sarcoma is among the most aggressive and least characterized soft-tissue sarcomas, treated with surgery plus radiation when localized and chemotherapy when metastatic. Immunotherapy development has been hampered by the tumor’s heterogeneity, variable antigens, low immune infiltration, and a shortage of patient-derived cell lines for preclinical work.
This study established and characterized JBT19, a new patient-derived UPS cell line. JBT19 cells express PD-L1 and collagen — the latter a ligand for the immune checkpoint molecule LAIR-1 — making the line a resource for studying two checkpoint axes in a sarcoma that has lacked preclinical models.
Key Discoveries
- JBT19: a new patient-derived undifferentiated pleomorphic sarcoma cell line
- Expresses PD-L1 and collagen, a ligand of the checkpoint receptor LAIR-1
- Addresses the shortage of UPS models for immunotherapy research
